Synta Announces Presentations at the 2013 European Cancer Congress
LEXINGTON, Mass. -- September 12, 2013
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled
presentations at the 2013 ECCO-ESMO-ESTRO European Cancer Congress in
Amsterdam, The Netherlands.
“Ganetespib in combination with docetaxel versus docetaxel alone in second
line adenocarcinoma patients with KRAS mutations and elevated LDH levels”
Abstract #: 3416
Date and Time: September 29, 2:00 – 4:30 PM CEST
Presenter: Dean Fennell, M.D., Ph.D., University of Leicester, United Kingdom
Interim results from the on-going GALAXY-1 Phase 2b/3 trial that were
previously presented at ASCO 2013 will be reviewed. Additional details on the
outcomes of patient subgroups with mutated KRAS and elevated LDH will also be
Synta expects that results from a future analysis of the GALAXY-1 trial will
be presented at the 2013 World Conference on Lung Cancer in Sydney, Australia
during the week of October 27.
“Antimetastatic activity of ganetespib: Preclinical studies and assessment of
progressions due to new lesions in the GALAXY-1 NSCLC trial”
Abstract #: 3517
Date: September 29, 2:00 – 4:30 PM CEST
Presenter: Vojo Vukovic, M.D., Ph.D., Synta Pharmaceuticals
Results demonstrating the anti-angiogenic and anti-metastatic properties of
ganetespib in preclinical cancer models will be presented.
Ganetespib, an investigational drug candidate, is a selective inhibitor of
heat shock protein 90 (Hsp90), a molecular chaperone which controls the
folding and activation of a number of client proteins that drive tumor
development and progression. Many solid and hematologic tumors are dependent
on Hsp90 client proteins including proteins involved in “oncogene addiction”
(ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, JAK2);
proteins involved in resistance to chemotherapy and radiation therapy (ATR,
BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in
angiogenesis (HIF-1alpha, VEGFR, PDFGR, and VEGF); and proteins involved in
metastasis (MET, RAF, AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical
models, inhibition of Hsp90 by ganetespib results in the inactivation,
destabilization, and eventual degradation of these cancer-promoting proteins.
Ganetespib is being evaluated in trials in lung cancer, breast cancer, and
other tumor types. The most common adverse event seen to date has been
transient, mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at
www.clinicaltrials.gov. Ganetespib has received Fast Track designation from
FDA for second-line treatment of non-small cell lung adenocarcinoma in
combination with docetaxel.
About the GALAXY Program
The GALAXY (Ganetespib Assessment in Lung cancer with docetaXel) program
consists of two randomized trials comparing the combination of ganetespib and
docetaxel versus docetaxel alone in patients with Stage IIIB/IV NSCLC who have
received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1)
to determine the patient population most likely to derive benefit from
ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2). More
information about the GALAXY trials can be found at www.clinicaltrials.gov
(NCT01348126 and NCT01798485).
About Lung Cancer
Lung cancer is the leading cause of cancer-related death in the world,
accounting for nearly 1.4 million deaths in 2008, according to the World
Health Organization. The five-year survival rate for this disease is
approximately 16%; over half of people with lung cancer die within one year of
being diagnosed. In the U.S., the American Cancer Society estimates that
228,000 cases of lung cancer will be diagnosed in 2013. Non-small cell
adenocarcinoma comprises about 40% of all lung cancer.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on
discovering, developing, and commercializing small molecule drugs to extend
and enhance the lives of patients with severe medical conditions, including
cancer and chronic inflammatory diseases. Synta has a unique chemical compound
library, an integrated discovery engine, and a diverse pipeline of clinical-
and preclinical-stage drug candidates with distinct mechanisms of action and
novel chemical structures. All Synta drug candidates were invented by Synta
scientists using our compound library and discovery capabilities. For more
information, please visit www.syntapharma.com
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified by the
use of forward-looking terminology such as "will", "would", "should",
"expects", "anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements, including statements relating to
the timing and content of announcements and expected developments in the
GALAXY-1 NSCLC trial, reflect our current views with respect to future events
and are based on assumptions and subject to risks and uncertainties that could
cause actual results to differ materially from those expressed or implied by
such forward-looking statements, including those described in "Risk Factors"
of our Form 10-K for the year ended December 31, 2012 as filed with the
Securities and Exchange Commission. Synta undertakes no obligation to publicly
update forward-looking statements, whether because of new information, future
events or otherwise, except as required by law.
Synta Pharmaceuticals Corp.
George Farmer, 781-541-7213
Andrea Rabney, 212-600-1494
Press spacebar to pause and continue. Press esc to stop.